Viatris signs definitive agreement to sell OTC business to Cooper Consumer Health

Viatris Inc

Viatris exercised put option on Jan 26, 2024; signed Transaction Agreement on Jan 29, 2024.
Sale includes substantially all OTC products business; consideration includes estimated cash and contingent additional amount (undisclosed).
Closing conditions include European Commission, French Ministry approvals; Italian and Serbian consents already obtained.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Viatris Inc entered into Transaction Agreement with Cooper Consumer Health SAS valued at purchase of substantially all of Viatris’ over-the-counter products business (effective 2024-01-29).

Action: entry
Agreement: asset purchase
Counterparty: Cooper Consumer Health SAS
Value: purchase of substantially all of Viatris’ over-the-counter products business
Effective: 2024-01-29

Exact text from the filing

on January 29, 2024, Viatris, Viatris Italia S.r.l., a wholly-owned subsidiary of Viatris, Ipex AB, a wholly-owned subsidiary of Viatris, and the Buyer Parties entered into the Transaction Agreement.

View on SEC.gov

Browse all material agreements →

Viatris Inc filing history →

Source: SEC EDGAR

accession 0001193125-24-019472

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.